Studies investigating the association between angiotensin-converting enzyme (ACE) insertion/deletion polymorphisms and the risk of acute respiratory distress syndrome (ARDS) report conflicting results. The objective of the present study was to summarize quantitatively the evidence for such a relationship. Two investigators independently searched the MEDLINE databases. This meta-analysis included six case-control studies, which included 514 ARDS cases and 2619 controls. The combined results based on all studies showed that patients with ARDS had a significantly higher frequency of the ACE deletion/deletion (DD) genotype (odds ratio [OR] 1.56; 95% confidence interval [CI] 1.22, 2.00) than controls. When stratifying for race, no significant differences in genotype distribution were found except that Caucasian patients with ARDS had a significantly higher frequency of the DD genotype (OR 1.65; 95% CI 1.27, 2.13) than controls. This meta-analysis suggests that ACE insertion/deletion polymorphisms may be associated with ARDS among Caucasians.
Introduction
Acute respiratory distress syndrome (ARDS) remains an important cause of death in the intensive care unit and few specific therapies are available. 1 Factors predicting the onset or severity of this syndrome are not well known, but the low incidence of ARDS within the relatively large group of patients at risk suggests the interaction of genetic and environmental factors. 2, 3 Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II and metabolizes kinins and many other biologically-active peptides. 4,5 An insertion/deletion of a 289 bp Alu repeat sequence polymorphism in intron 16 of the human ACE gene has been associated with 28 -47% of the variation in circulating ACE Z Hu, X Jin, Y Kang et al. ACE gene polymorphism associated with ARDS levels in healthy subjects, and high plasma ACE levels have been shown to be associated with the deletion/deletion (DD) genotype. 6, 7 The association of the ACE insertion/ deletion polymorphism with many clinical entities has been widely studied. Experimental evidence suggests that activation of the pulmonary reninangiotensin system influences the pathogenesis of ARDS by increasing vascular permeability. 8 -10 Over the last 10 years, a number of casecontrol studies have been conducted to investigate the association between the ACE insertion/deletion polymorphism and the risk of ARDS in humans, but these studies have reported conflicting results. 11 No quantitative summary of the evidence has ever been performed. The purpose of the present meta-analysis was to summarize quantitatively the evidence relating to any relationship between ACE insertion/deletion polymorphism and ARDS risk.
Materials and methods

LITERATURE SEARCH STRATEGY
A literature search was applied to the following electronic databases: MEDLINE (January 1966 -October 2009) and EMBASE (January 1980 -October 2009). The following key words were used: 'angiotensin converting enzyme' or 'ACE', and 'acute respiratory distress syndrome' or 'ARDS'. The search was done without any restriction on language, but only included studies conducted in human subjects. The reference lists of reviews and retrieved articles were hand searched simultaneously and independently by two investigators (Z.H., X.J.). Abstracts or unpublished reports were not considered. If more than one article was published by the same author using the same case series, the study with the higher sample size was selected.
INCLUSION AND EXCLUSION CRITERIA
The abstracts of all citations and retrieved studies were reviewed. For inclusion in the meta-analysis, the identified articles had to provide information on: (i) the number of ARDS cases and controls studied; and (ii) the number of individuals genotyped (insertion/ insertion [II], insertion/deletion [ID] and deletion/deletion [DD]) for both cases and controls. Major reasons for exclusion of studies were: (i) no control; (ii) duplicate data; and (iii) no usable data reported.
DATA EXTRACTION
All data were extracted independently by two reviewers according to the pre-specified selection criteria (Z.H., X.J.). Disagreement was resolved by discussion. The following data were extracted: study design and period, statistical methods, population, number of ARDS cases and controls studied, and study results.
STATISTICAL ANALYSIS
The statistical analysis was conducted using STATA 8.2 (StataCorp, College Station, TX, USA). A P-value < 0.05 was considered to be statistically significant. Dichotomous data are presented as the odds ratio (OR) with 95% confidence interval (CI). Statistical heterogeneity was measured using the Q statistic and P < 0.10 was considered representative of statistically significant heterogeneity. Heterogeneity was also assessed through visual examination of L'Abbé plots. A fixed-effects model was used when there was no heterogeneity of the results of the trials. Otherwise, the randomeffects model was used. For dichotomous outcomes, patients with incomplete or missing data were included in sensitivity analyses by counting them as treatment failures. To establish the effect of clinical Z Hu, X Jin, Y Kang et al. ACE gene polymorphism associated with ARDS heterogeneity between studies on the conclusions of the meta-analysis, a subgroup analysis was conducted on the basis of race. Several methods were used to assess the potential for publication bias, including visual inspection of asymmetry in funnel plots, the Begg rank correlation method and the Egger weighted regression method; P < 0.05 was considered to be representative of statistically significant publication bias. 12, 13 
Results
STUDY CHARACTERISTICS
There were 62 papers identified using the key search words. Following screening of the title, 30 of these articles were excluded (23 were not on gene polymorphisms, four were not case-control studies and three were not conducted in humans). Abstracts from the remaining 32 articles were reviewed and an additional 19 trials were then excluded (eight were not case-control studies and 11 were not conducted in humans), leaving 13 studies for full publication review. Of these, eight were excluded (six were not on ARDS and two did not report usable data); thus, five papers, 14 -18 which included 514 ARDS cases and 2619 controls, were found to match the study inclusion criteria. These five papers included six studies (two populationbased case-control studies and four hospitalbased case-control studies), and they were included in this meta-analysis. The studies had been carried out in China, UK, Germany and Spain and their characteristics are presented in Table 1 .
QUANTITATIVE DATA SYNTHESIS
The combined results based on all studies showed that patients with ARDS only had a significantly higher frequency of the DD genotype (OR 1.56; 95% CI 1.22, 2.00) than controls (Figs 1 -3 ). There was no significant difference between ARDS patients and controls in terms of the frequency of the II or ID genotypes. When stratifying for race, no significant differences in genotype distribution were found, except that Caucasian patients with ARDS had a significantly higher frequency of the DD genotype (OR 1.65; 95% CI 1.27, 2.13) than controls (Fig. 3 ).
Statistically significant heterogeneity was observed between trials in one analysis with the Q statistic for the II genotype (P = 0.02), but not for the ID or DD genotypes. In addition, L'Abbe plots showed evidence of heterogeneity. Review of funnel plots could not rule out the potential for publication bias for all analyses. Publication bias was not evident when the Begg rank correlation method and the Egger weighted regression method were used.
Discussion
Meta-analysis has been gradually used in medicine to improve the statistical efficiency, to evaluate the disadvantages of formulated research and hypotheses, and to reach reliable conclusions from the mixed assortment of potentially relevant studies in order to determine the most promising directions for future research. The rapid growth of human genetics creates countless opportunities for studies of disease association. Given the number of potentially identifiable genetic markers and the multitude of clinical outcomes to which these may be linked, the testing and validation of statistical hypotheses in genetic epidemiology is a task of unprecedented scale. Meta-analysis provides a quantitative approach for combining the results of various studies on the same topic, and for estimating and explaining their diversity. 19 In the present meta-analysis, statistically significant heterogeneity was observed 
TABLE 1: Characteristics of the five hospital-and population-based case-control studies investigating the association between angiotensin-converting enzyme (ACE) insertion/deletion polymorphisms and acute respiratory distress syndrome (ARDS)
included in the meta-analysis 14 -18
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between trials in only one analysis with the Q statistic. The most important factor that contributed to the heterogeneity was whether or not the genotype frequencies were in Hardy-Weinberg equilibrium, because the equilibrium may not hold among a case Marshall et al., 14 2002 Adamzik et al., 17 Observed departures from equilibrium suggested possible issues with the control group or the study population in general, which might have generated less than ideal circumstances for the investigation of the ACE insertion/deletion polymorphism and ARDS. A departure from the Hardy-Weinberg equilibrium can also imply possible ethnic admixture in the population, if the polymorphic site varies in genotype by race. 20 In the present metaanalysis, subgroup analysis was conducted on the basis of race; two studies were conducted among Asians and four studies were conducted among Caucasians. When stratifying for race, Caucasian patients with ARDS had a significantly higher frequency of the DD genotype than controls. This is the first report to summarize quantitatively the evidence for the association between the ACE insertion/ deletion polymorphism and ARDS risk. The strength of this association suggests a major role for the renin-angiotensin system in the development and progression of ARDS. This finding might be applied clinically in a number of ways. In principle, the administration of an ACE inhibitor would modulate the effective phenotype of a patient from that of a DD individual to that of an ID or II individual. Thus, ACE inhibitors might lower the risk of developing ARDS in an at-risk group or reduce the severity of disease and improve outcome in those with established lung injury. Knowing the genotype of a patient could also help target therapy, such that only patients with a D allele or DD genotype might be given an ACE inhibitor to prevent the onset of ARDS. Further study is required to delineate the precise mechanisms involved and, potentially, to facilitate the design of effective clinical trials. 21 There are some limitations to this metaanalysis. First, only published studies were 
